An Inducible Neural Stem Progenitor Cell Model for Testing Therapeutic Interventions Against Neurodegeneration FENIB
Drug Development Research · 2025
DOI: 10.1002/ddr.70041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Alessandro Giustini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Biotechnologies 'Charles Darwin', Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Neural Stem Cells, Neuroserpin, Serpins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by Sapienza University of Rome, Italy (Sapienza Research Grants 2021), Fondazione Telethon - Italy, Grantn.GMR23T1217.
Abstract (Originalsprache)
Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is a neurodegenerative pathology caused by accumulation of mutant neuroserpin (NS) polymers inside the endoplasmic reticulum (ER) of neurons, leading to cellular toxicity and neuronal death. To date, there is no cure for FENIB, and only palliative care is available for FENIB patients, underlining the urgency to develop therapeutic strategies. The purpose of this work was to create a cellular system designed for testing small molecules able to reduce the formation of NS polymers. Our results show the generation and characterisation of a novel cell culture model for FENIB based on neural stem progenitor cells (NPCs) with inducible expression of either wild type (WT) or G392E NS, a variant that causes severe FENIB. We also report the use of these novel cell lines to explore the effects of four different proteolysis targeting chimaera (PROTAC) compounds, small bivalent molecules engineered to bind to the E3 ubiquitin ligase cereblon, and to NS through a recruiting motif based on the small molecule embelin. This approach aims to enhance the degradation of mutant NS after retro‐translocation to the cytosol by facilitating its targeting to the proteasome. Our results show little toxicity and no variation in NS levels with any of the compounds tested. In conclusion, this work sets the basis for future attempts to identify molecules able to prevent NS accumulation inside the ER of cultured cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology and Biotechnologies 'Charles Darwin', Sapienza University of Rome, Rome, Italy.
- Department of Chemistry, University of Milan, Milan, Italy.
ORCID-Profile: Elena Miranda
Förderung
- This work was supported by Sapienza University of Rome, Italy (Sapienza Research Grants 2021)
- Fondazione Telethon - Italy, Grantn.GMR23T1217
Zitieren
APA
Giustini, A., Maiocchi, A., Serangeli, I., Pedrini, M., Quintiliani, A., Sabato, V., Bonato, F., Seneci, P., Lupo, G., Passarella, D., & Miranda, E. (2025). An Inducible Neural Stem Progenitor Cell Model for Testing Therapeutic Interventions Against Neurodegeneration FENIB. Drug Development Research. https://doi.org/10.1002/ddr.70041
Vancouver
Giustini A, Maiocchi A, Serangeli I, Pedrini M, Quintiliani A, Sabato V, et al. An Inducible Neural Stem Progenitor Cell Model for Testing Therapeutic Interventions Against Neurodegeneration FENIB. Drug Development Research. 2025. doi:10.1002/ddr.70041
BibTeX
@article{Giustini2025,
author = {Giustini, Alessandro and Maiocchi, Alice and Serangeli, Ilaria and Pedrini, Martina and Quintiliani, Anna and Sabato, Valentina and Bonato, Francesca and Seneci, Pierfausto and Lupo, Giuseppe and Passarella, Daniele and Miranda, Elena},
title = {An Inducible Neural Stem Progenitor Cell Model for Testing Therapeutic Interventions Against Neurodegeneration FENIB},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70041}
}
EUVIMED